Spyre Therapeutics, Inc. financial data

Symbol
SYRE on Nasdaq
Industry
Pharmaceutical Preparations
Location
221 Crescent Street, Building 23, Suite 105, Waltham, MA
State of incorporation
DE
Fiscal year end
December 31
Former names
Aeglea BioTherapeutics, Inc. (to 11/24/2023)
Latest financial report
10-Q/A - Q3 2024 - Nov 18, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.09K % +501%
Debt-to-equity 29.9 %
Return On Equity -82.8 % -126%
Return On Assets -51 % +75.1%
Operating Margin -39.4K % -480%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 51.4M shares +1170%
Common Stock, Shares, Outstanding 51.4M shares +1169%
Entity Public Float 26.2M USD -13.5%
Common Stock, Value, Issued 12K USD +71.4%
Weighted Average Number of Shares Outstanding, Basic 50.9M shares +1085%
Weighted Average Number of Shares Outstanding, Diluted 50.9M shares +1085%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 0 USD -100%
Research and Development Expense 55.4M USD -11%
General and Administrative Expense 49.1M USD +58.6%
Operating Income (Loss) -193M USD +10.4%
Nonoperating Income (Expense) -21.6M USD +72.6%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -215M USD +27%
Income Tax Expense (Benefit) 50K USD +31.6%
Net Income (Loss) Attributable to Parent -215M USD +27%
Earnings Per Share, Basic -20 USD/shares -219%
Earnings Per Share, Diluted -20 USD/shares -219%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 71.6M USD -21%
Cash, Cash Equivalents, and Short-term Investments 426M USD
Assets, Current 421M USD +104%
Property, Plant and Equipment, Net 0 USD -100%
Operating Lease, Right-of-Use Asset 0 USD -100%
Other Assets, Noncurrent 10K USD +11.1%
Assets 421M USD +103%
Accounts Payable, Current 2.85M USD +45.8%
Contract with Customer, Liability, Current 0 USD -100%
Liabilities, Current 57.5M USD +28.2%
Contract with Customer, Liability, Noncurrent 0 USD -100%
Operating Lease, Liability, Noncurrent 0 USD -100%
Other Liabilities, Noncurrent 0 USD -100%
Liabilities 93.7M USD +42.9%
Accumulated Other Comprehensive Income (Loss), Net of Tax 1.46M USD
Retained Earnings (Accumulated Deficit) -916M USD -30.6%
Stockholders' Equity Attributable to Parent 327M USD
Liabilities and Equity 421M USD +103%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -28.5M USD -61.9%
Net Cash Provided by (Used in) Financing Activities 172M USD
Net Cash Provided by (Used in) Investing Activities -105M USD -691%
Common Stock, Shares Authorized 400M shares +1900%
Common Stock, Shares, Issued 51.4M shares +1169%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 38.7M USD +28116%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 71.6M USD -22.1%
Deferred Tax Assets, Valuation Allowance 125M USD +16.6%
Deferred Tax Assets, Gross 125M USD +15.8%
Operating Lease, Liability 4.63M USD -8.23%
Payments to Acquire Property, Plant, and Equipment 37K USD -91.8%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -213M USD +27.5%
Lessee, Operating Lease, Liability, to be Paid 6.07M USD -13.3%
Property, Plant and Equipment, Gross 0 USD -100%
Operating Lease, Liability, Current 0 USD -100%
Lessee, Operating Lease, Liability, to be Paid, Year Two 1.1M USD +3.67%
Lessee, Operating Lease, Liability, to be Paid, Year One 1.08M USD +13.7%
Operating Lease, Weighted Average Discount Rate, Percent 0 pure -104%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 1.45M USD -26.2%
Lessee, Operating Lease, Liability, to be Paid, Year Three 1.13M USD +3.01%
Deferred Tax Assets, Operating Loss Carryforwards 74.5M USD +8.03%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 8.64M shares -13.6%
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 1.16M USD +3.01%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 0 USD -100%
Share-based Payment Arrangement, Expense 13.1M USD +174%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%